Cassiopea S.P.A.
Records under this name other than the patents Cassiopea S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,433,628 | Enzymatic Process for Obtaining 17 Alpha- Monoesters of Cortexolone And/Or Its 9,11- Dehydroderivatives Formerly held In force · High confidence | In force | High confidence | |
| US 9,700,536 | Topical formulations of tellurium-containing compounds Lapsed on the fee record Ended Jul 11, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jul 11, 2025 | From the USPTO record |
| US 9,216,197 | Topical formulations of tellurium-containing compounds Lapsed on the fee record Ended Dec 22, 2023 · From the USPTO record | Lapsed on the fee record | Ended Dec 22, 2023 | From the USPTO record |
| US 8,143,240 | 17ALPHA, 21-Dihydroxypregnene Esters as Antiandrogenic Agents Term ended Term ended Jan 12, 2023 · Medium confidence | Term ended | Term ended Jan 12, 2023 | Medium confidence |
| US 9,895,379 | 17alpha, 21-dihydroxypregnene esters as antiandrogenic agents Term ended Term ended Sep 27, 2022 · From the USPTO record | Term ended | Term ended Sep 27, 2022 | From the USPTO record |
| US 8,865,690 | 17ALFA, 21-Dihydroxypregnene Esters as Antiandrogenic Agents Term ended Ended no later than Jul 24, 2022 · Low confidence | Term ended | Ended no later than Jul 24, 2022 | Low confidence |
| US 9,211,295 | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents Formerly held Term ended Ended no later than Jul 24, 2022 · From the USPTO record | Term ended | Ended no later than Jul 24, 2022 | From the USPTO record |
| US 8,703,753 | Use of tellurium compounds for the treatment of actinic keratosis Lapsed on the fee record Ended Apr 22, 2022 · From the USPTO record | Lapsed on the fee record | Ended Apr 22, 2022 | From the USPTO record |
| US 8,623,908 | Use of tellurium compounds for inhibition of interleukin-converting enzyme Lapsed on the fee record Ended Jan 7, 2022 · From the USPTO record | Lapsed on the fee record | Ended Jan 7, 2022 | From the USPTO record |
| US 6,472,381 | Method of treating psoriasis Term ended Term ended Oct 12, 2021 · From the USPTO record | Term ended | Term ended Oct 12, 2021 | From the USPTO record |